Retatrutide shows promise for knee pain and weight loss in early trials

Phase 3 trials with over 1,000 adults found two-thirds of retatrutide users reported at least 50% reduction in knee osteoarthritis pain, with average weight loss up to 25%.

Retatrutide, a triple-hormone receptor agonist GLP-1 drug developed by Eli Lilly, demonstrated in Phase 3 clinical trials that two-thirds of participants reported at least 50% reduction in knee osteoarthritis pain. The average body weight loss reached up to 25% in trial users, while the placebo group self-reported a 38% reduction in knee pain. The study, published in the New England Journal of Medicine, notes weight loss likely reduces mechanical stress on joints. However, the U.S. Food and Drug Administration has approved retatrutide for compassionate use in only one participant, and the exact mechanism for pain relief remains unclear. Efficacy in non-overweight individuals is unconfirmed. This approach may address both knee osteoarthritis and obesity simultaneously, potentially lowering healthcare costs for millions. The source details only trial results and does not address real-world application.

Source: New Atlas